Skip to Content
You are currently on the new version of our website. Access the old version .

1,000 Results Found

  • Article
  • Open Access
13 Citations
5,591 Views
14 Pages

Statistical Evaluation of Barkhausen Noise Testing (BNT) for Ground Samples

  • Robert Tomkowski,
  • Aki Sorsa,
  • Suvi Santa-aho,
  • Per Lundin and
  • Minnamari Vippola

30 October 2019

Barkhausen noise testing (BNT) is a nondestructive method for investigating many properties of ferromagnetic materials. The most common application is the monitoring of grinding burns caused by introducing locally high temperatures while grinding. Ot...

(This article belongs to the Section Physical Sensors)
  • Article
  • Open Access
3 Citations
1,981 Views
14 Pages

28 July 2025

This study evaluates the effect of zirconium (Zr) incorporation on the structural, microstructural, and functional properties of lead-free ceramics based on the 0.95(Bi0.5Na0.5)TiO3–0.05BaTiO3 (BNT–5BT) system. Two distinct doping strateg...

(This article belongs to the Special Issue Nanomaterials for Sustainable Waste Conversion, Energy Production, and Environmental Applications)
  • Article
  • Open Access
4 Citations
2,098 Views
12 Pages

Enhancement of Energy Storage Performance in NaNbO3-Modified BNT-ST Ceramics

  • Erping Wang,
  • Hongjun Yang,
  • Haizhou Guo,
  • Hongxia Li and ,
  • Haosong Zhang,
  • Jinyu Li,
  • Mingsai Gu,
  • Tao Yang and
  • Yangyang Zhang
  • + 4 authors+ 0 author

23 April 2025

Relaxor ferroelectrics based on sodium bismuth titanate (Bi0.5Na0.5TiO3, BNT) have attracted more interest recently as potential ecologically acceptable materials for pulse power technology because of their excellent full-energy storage capabilities....

  • Article
  • Open Access
4 Citations
3,645 Views
11 Pages

Fabrication and Characterization of Lead-Free BNT-6BT Ultrasonic Transducers Designed by an Intelligent Optimization Algorithm

  • Junshan Zhang,
  • Jianxin Zhao,
  • Yi Quan,
  • Jingrong He and ,
  • Yi Li,
  • Zhe Wang,
  • Kun Zheng,
  • Jian Zhuang,
  • Zhishui Jiang and
  • Wei Ren
  • + 6 authors+ 1 author

22 August 2022

Lead-free piezoelectric material-based ultrasonic transducers have been researched for several years, but the inefficient properties and design difficulties have troubled lead-free ultrasonic transducers for a long time. To improve the performance an...

(This article belongs to the Special Issue Lead-free Ferro-/Piezoelectric Ceramics and Thin Films)
  • Article
  • Open Access
13 Citations
6,437 Views
9 Pages

Fabrication and Characterization of High-Frequency Ultrasound Transducers Based on Lead-Free BNT-BT Tape-Casting Thick Film

  • Junshan Zhang,
  • Wei Ren,
  • Yantao Liu,
  • Xiaoqing Wu and ,
  • Chunlong Fei,
  • Yi Quan and
  • Qifa Zhou
  • + 2 authors+ 0 author

19 September 2018

A lead-free 0.94(Na0.5Bi0.5) TiO3-0.06 BaTiO3 (BNT-BT) thick film, with a thickness of 60 μm, has been fabricated using a tape-casting method. The longitudinal piezoelectric constant, clamped dielectric permittivity constant, remnant polarization...

(This article belongs to the Special Issue Ultrasound Transducers)
  • Article
  • Open Access
76 Citations
11,480 Views
16 Pages

Comparative Study of Ferroelectric and Piezoelectric Properties of BNT-BKT-BT Ceramics near the Phase Transition Zone

  • David Andres Fernandez-Benavides,
  • Aixa Ibeth Gutierrez-Perez,
  • Angelica Maria Benitez-Castro,
  • Maria Teresa Ayala-Ayala and ,
  • Barbara Moreno-Murguia and
  • Juan Muñoz-Saldaña
  • + 1 author+ 0 author

1 March 2018

We report a comprehensive comparative study of ferroelectric and piezoelectric properties of BNT-BKT-BT ceramics through the MPB (morphotropic phase boundary) zone, from the rhombohedral to the tetragonal phases in the system (97.5−x)(Bi0.5Na0.5)TiO3...

  • Article
  • Open Access
17 Citations
4,579 Views
19 Pages

Background: After the start of the worldwide COVID-19 vaccination campaign, there were increased reports of autoimmune diseases occurring de novo after vaccination. This in silico analysis aimed to investigate the presence of protein epitopes encoded...

(This article belongs to the Special Issue Microbial Infections and Rheumatic Diseases)
  • Article
  • Open Access
1,291 Views
17 Pages

16 November 2025

This work presents a comparative study on the structural, microstructural, and functional properties of a novel lead-free solid solution based on (1−x)(0.95(Bi0.5Na0.5)TiO3–0.05BaTiO3)–x(0.5Ba0.7Ca0.3TiO3–0.5BaTi0.8Zr0.2O3), a...

(This article belongs to the Special Issue Nanomaterials for Sustainable Waste Conversion, Energy Production, and Environmental Applications)
  • Review
  • Open Access
3,156 Views
23 Pages

Mechanistic Insights into Off-the-Shelf vs. Personalized mRNA Cancer Vaccines: A Comparative Review of BNT111 and BNT122

  • Cheska Jane A. Cudog,
  • Trisha Anne A. Arcilla,
  • Angel Mae D. Gregorio,
  • Samantha D. Ramos and ,
  • Eunice S. Salazar,
  • Jenny L. Sindingan,
  • Marianne Joy L. Tubalinal,
  • Huai-Ying Huang,
  • Po-Hua Wu and
  • Brian Harvey Avanceña Villanueva
  • + 7 authors+ 2 authors

22 May 2026

mRNA vaccines are a relevant approach in cancer immunotherapy, using messenger RNA to induce immune responses against tumor-associated antigens. In this review, BNT111 and BNT122 are compared as representative off-the-shelf and personalized models. B...

  • Communication
  • Open Access
3 Citations
2,809 Views
11 Pages

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2

  • Rieke Reiter,
  • Pia Von Blanckenburg,
  • Reinier Mutters,
  • Julia Thiemer and ,
  • Reinhard Geßner and
  • Ulf Seifart
  • + 1 author+ 0 author

Emerging numbers of SARS-CoV-2 infections are currently combated with a third vaccination. Considering the different vaccination regimens used for the first two vaccine doses, we addressed whether the previous vaccination influences the immune respon...

(This article belongs to the Special Issue Effectiveness, Safety and Immunogenicity of SARS-CoV-2 Vaccines)
  • Article
  • Open Access
9 Citations
4,701 Views
11 Pages

Evaluation of Antibody Response to Heterologous Prime–Boost Vaccination with ChAdOx1 nCoV-19 and BNT162b2: An Observational Study

  • Davide Firinu,
  • Andrea Perra,
  • Marcello Campagna,
  • Roberto Littera and ,
  • Federico Meloni,
  • Francesca Sedda,
  • Maria Conti,
  • Giulia Costanzo,
  • Monica Erbi and
  • Luchino Chessa
  • + 12 authors+ 7 authors

14 December 2021

In several countries, thrombotic events after vaccination with ChAdOx1 nCoV-19 have led to heterologous messenger RNA (mRNA) boosting. We tested the antibody response to SARS-CoV-2 spike protein four weeks after heterologous priming with the ChAdOx1...

(This article belongs to the Special Issue The COVID Vaccine)
  • Article
  • Open Access
16 Citations
4,889 Views
8 Pages

An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines

  • Alexandre Vallée,
  • Marc Vasse,
  • Laurence Mazaux,
  • Brigitte Bonan and ,
  • Carline Amiel,
  • Sara Zia-Chahabi,
  • Aurélie Chan-Hew-Wai,
  • Eric Farfour,
  • Eve Camps and
  • Erwan Fourn
  • + 9 authors+ 4 authors

25 August 2021

Background: There is a small amount of immunological data on COVID-19 heterologous vaccination schedules in humans. We assessed the immunogenicity of BNT162b2 (Pfizer/BioNTech) administered as a second dose in healthcare workers primed with ChAdOx1-S...

(This article belongs to the Special Issue COVID-19: Clinical Advances and Challenges)
  • Communication
  • Open Access
22 Citations
5,258 Views
12 Pages

Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222

  • Evangelos Terpos,
  • Vangelis Karalis,
  • Ioannis Ntanasis-Stathopoulos,
  • Zoi Evangelakou and ,
  • Maria Gavriatopoulou,
  • Maria S. Manola,
  • Panagiotis Malandrakis,
  • Despoina D. Gianniou,
  • Efstathios Kastritis and
  • Meletios A. Dimopoulos
  • + 6 authors+ 1 author

Along with their level of protection against COVID-19, SARS-CoV-2-specific antibodies decline over time following vaccination with BNT162b2. However, relevant data on AZD1222 are scarce. In this context, the aim of this study was to compare SARS-CoV-...

(This article belongs to the Special Issue Immunology in COVID-19 Disease: From Pathophysiology to Novel Therapeutic Approaches)
  • Article
  • Open Access
1 Citations
2,876 Views
17 Pages

Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac

  • Diego A. Díaz-Dinamarca,
  • Simone Cárdenas-Cáceres,
  • Nicolás A. Muena,
  • Pablo Díaz and ,
  • Gisselle Barra,
  • Rodrigo Puentes,
  • Daniel F. Escobar,
  • Michal Díaz-Samirin,
  • Natalia T. Santis-Alay and
  • Abel E. Vasquez
  • + 11 authors+ 6 authors

15 August 2024

The SARS-CoV-2 Omicron variant and its sublineages continue to cause COVID-19-associated pediatric hospitalizations, severe disease, and death globally. BNT162b2 and CoronaVac are the main vaccines used in Chile. Much less is known about the Wuhan-Hu...

(This article belongs to the Special Issue Humoral and Cellular Response after COVID-19 Vaccination)
  • Article
  • Open Access
3 Citations
2,991 Views
12 Pages

Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine

  • Éva Rákóczi,
  • Gusztáv Magócs,
  • Sára Kovács,
  • Béla Nagy and ,
  • Gabriella Szűcs and
  • Zoltán Szekanecz
  • + 1 author+ 0 author

Objectives: In this prospective study, SARS-CoV−2 spike protein specific total immunoglobulin (Ig) levels were analyzed before and after BNT162 b2 mRNA booster vaccination in individuals previously administered with two doses of BBIBP-CorV vacc...

(This article belongs to the Section Diagnostic Microbiology and Infectious Disease)
  • Article
  • Open Access
116 Citations
2,318,122 Views
12 Pages

Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line

  • Markus Aldén,
  • Francisko Olofsson Falla,
  • Daowei Yang,
  • Mohammad Barghouth and ,
  • Cheng Luan,
  • Magnus Rasmussen and
  • Yang De Marinis
  • + 2 authors+ 0 author

25 February 2022

Preclinical studies of COVID-19 mRNA vaccine BNT162b2, developed by Pfizer and BioNTech, showed reversible hepatic effects in animals that received the BNT162b2 injection. Furthermore, a recent study showed that SARS-CoV-2 RNA can be reverse-transcri...

(This article belongs to the Topic Clinical, Translational and Basic Research on Liver Diseases)
  • Systematic Review
  • Open Access
9 Citations
7,468 Views
29 Pages

Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review

  • Constantina Boikos,
  • Kassandra Schaible,
  • Solange Nunez-Gonzalez,
  • Verna Welch and ,
  • Tianyan Hu,
  • Moe Hein Kyaw,
  • Laura Elizabeth Choi,
  • Joanna Kamar,
  • Henry Goebe and
  • John McLaughlin
  • + 5 authors+ 0 author

2 April 2025

Background/Objectives: Co-administration of BNT162b2 with licensed seasonal influenza vaccines (SIVs) is recommended by health authorities. We provide a comprehensive summary of the data supporting this practice in adults. Methods: This systematic re...

(This article belongs to the Special Issue Vaccines and Vaccine Preventable Diseases)
  • Article
  • Open Access
8 Citations
8,802 Views
15 Pages

Adverse Events Associated with BNT162b2 and AZD1222 Vaccines in the Real World: Surveillance Report in a Single Italian Vaccine Center

  • Maria Costantino,
  • Carmine Sellitto,
  • Valeria Conti,
  • Graziamaria Corbi and ,
  • Francesco Marongiu,
  • Giovanni Genovese,
  • Giuseppina Moccia,
  • Mario Capunzo,
  • Anna Borrelli and
  • Francesco De Caro
  • + 10 authors+ 5 authors

4 March 2022

Aim: Despite huge efforts in developing specific drugs, vaccination represents the only effective strategy against COVID-19. Efficacy and safety of the COVID-19 vaccines were established during clinical trials. Nonetheless, it is very important to pe...

(This article belongs to the Topic Fighting against COVID-19: Latest Advances, Challenges and Methodologies)
  • Communication
  • Open Access
10 Citations
3,379 Views
11 Pages

Immunogenicity and Safety of the BNT162b2 COVID-19 Vaccine in Patients with Cystic Fibrosis with or without Lung Transplantation

  • Francesca Lucca,
  • Valentino Bezzerri,
  • Elisa Danese,
  • Debora Olioso and ,
  • Denise Peserico,
  • Christian Boni,
  • Giulia Cucchetto,
  • Martina Montagnana,
  • Gloria Tridello and
  • Marco Cipolli
  • + 8 authors+ 3 authors

Cystic fibrosis (CF) is characterized by a progressive decline in lung function, which may be further impaired by viral infections. CF is therefore considered a comorbidity of coronavirus disease 2019 (COVID-19), and SARS-CoV-2 vaccine prioritization...

(This article belongs to the Special Issue COVID-19 Pandemic: Therapeutic Strategies and Vaccines)
  • Review
  • Open Access
14 Citations
7,922 Views
17 Pages

Effectiveness of BNT162b2 and mRNA-1273 Vaccines against COVID-19 Infection: A Meta-Analysis of Test-Negative Design Studies

  • Shuailei Chang,
  • Hongbo Liu,
  • Jian Wu,
  • Wenwei Xiao and ,
  • Sijia Chen,
  • Shaofu Qiu,
  • Guangcai Duan,
  • Hongbin Song and
  • Rongguang Zhang
  • + 4 authors+ 0 author

18 March 2022

Although numerous COVID-19 vaccines are effective against COVID-19 infection and variants of concern (VOC) in the real world, it is imperative to obtain evidence of the corresponding vaccine effectiveness (VE). This study estimates the real-world eff...

(This article belongs to the Special Issue Prevention of SARS-CoV-2 Infection and COVID-19: Safety, Immunogenicity and Effectiveness of Available Vaccines)
  • Case Report
  • Open Access
16 Citations
15,024 Views
10 Pages

Clinical and Molecular Characterization of a Rare Case of BNT162b2 mRNA COVID-19 Vaccine-Associated Myositis

  • Eli Magen,
  • Sumit Mukherjee,
  • Mahua Bhattacharya,
  • Rajesh Detroja and ,
  • Eugene Merzon,
  • Idan Blum,
  • Alejandro Livoff,
  • Mark Shlapobersky,
  • Gideon Baum and
  • Milana Frenkel-Morgenstern
  • + 8 authors+ 3 authors

16 July 2022

Initial clinical trials and surveillance data have shown that the most commonly administered BNT162b2 COVID-19 mRNA vaccine is effective and safe. However, several cases of mRNA vaccine-induced mild to moderate adverse events were recently reported....

(This article belongs to the Special Issue Adverse Events of COVID-19 Vaccines)
  • Article
  • Open Access
6 Citations
2,376 Views
10 Pages

Association between Adverse Reactions and Humoral Immune Response No Longer Detectable after BNT162b2 Booster Vaccination

  • Stilla Bauernfeind,
  • Sebastian Einhauser,
  • Leonid Tydykov,
  • Anna-Lena Mader and ,
  • Bernd Salzberger,
  • Florian Hitzenbichler,
  • Arno Mohr,
  • Ralph Burkhardt,
  • Ralf Wagner and
  • David Peterhoff
  • + 5 authors+ 0 author

25 September 2022

In a previous study, we described a highly significant association between reactogenicity and SARS-CoV-2 RBD IgG titers and wild-type neutralization capacity in males after basic vaccination with BNT162b2. The objective of this study was to assess wh...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Article
  • Open Access
15 Citations
3,108 Views
9 Pages

Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine

  • Sung-Hee Lim,
  • Seong-Hyeok Choi,
  • Bora Kim,
  • Ji-Youn Kim and ,
  • Young-Sok Ji,
  • Se-Hyung Kim,
  • Chan-Kyu Kim,
  • Tark Kim,
  • Eun-Ju Choo and
  • Seong-Kyu Park
  • + 7 authors+ 2 authors

24 November 2021

The COVID-19 pandemic is changing rapidly and requires different strategies to maintain immunization. In Korea, different COVID-19 vaccines are recommended and available for various populations, including healthcare workers (HCWs) at high risk of SAR...

  • Case Report
  • Open Access
18 Citations
19,210 Views
7 Pages

Pyoderma Gangrenosum Induced by BNT162b2 COVID-19 Vaccine in a Healthy Adult

  • Mazin Barry,
  • Abdulaziz AlRajhi and
  • Khaldoon Aljerian

7 January 2022

(1) Background: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis of unknown etiology. Coronavirus disease 2019 (COVID-19) vaccines can cause a variety of adverse cutaneous manifestations. PG associated with mRNA vaccines has not previously...

  • Article
  • Open Access
4 Citations
2,902 Views
9 Pages

Late Hypersensitivity Reactions to the BNT162b2 SARS-CoV-2 Vaccine Are Linked to Delayed Skin Sensitization and Prior Exposure to Hyaluronic Acid

  • Ramit Maoz-Segal,
  • Ronen Shavit,
  • Mona Iancovici Kidon,
  • Irena Offengenden and ,
  • Diti Machnes-Maayan,
  • Yulia Lifshitz-Tunitsky,
  • Stanley Niznik and
  • Nancy Agmon-Levin
  • + 3 authors+ 0 author

3 December 2022

Background: Late hypersensitivity reactions (HSRs) to the BNT162b2-vaccine have raised concerns regarding its safety, particularly as further immunizations are required. The yield of skin testing with the BNT162b2v is unclear, as well as the risk fac...

(This article belongs to the Section Epidemiology)
  • Review
  • Open Access
13 Citations
18,206 Views
16 Pages

Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies

  • Shin-Jie Yong,
  • Alice Halim,
  • Michael Halim,
  • Abbas Al Mutair and ,
  • Saad Alhumaid,
  • Jehad Al-Sihati,
  • Hawra Albayat,
  • Mohammed Alsaeed,
  • Mohammed Garout and
  • Ali A. Rabaan
  • + 10 authors+ 5 authors

2 July 2022

Given the increasing anti-vaccine movements erroneously touting vaccine danger, this review has investigated the rare adverse events potentially associated with BNT162b2 (Pfizer-BioNTech), an mRNA vaccine against the severe acute respiratory distress...

(This article belongs to the Special Issue Vaccine Safety)
  • Article
  • Open Access
10 Citations
3,050 Views
6 Pages

Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2

  • Marcello Salvaggio,
  • Federica Fusina,
  • Filippo Albani,
  • Maurizio Salvaggio and ,
  • Rasula Beschi,
  • Emanuela Ferrari,
  • Alberto Costa,
  • Laura Agnoletti,
  • Emanuela Facchi and
  • Giuseppe Natalini
  • + 5 authors+ 0 author

17 September 2021

The Pfizer/BioNtech Comirnaty vaccine (BNT162b2 mRNA COVID-19) against SARS-CoV-2 is currently in use in Italy. Antibodies to evaluate SARS-CoV-2 infection prior to administration are not routinely tested; therefore, two doses may be administered to...

(This article belongs to the Section Infectious Diseases)
  • Brief Report
  • Open Access
12 Citations
4,662 Views
9 Pages

Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial

  • Juleen Gayed,
  • Vishva Bangad,
  • Xia Xu,
  • Federico Mensa and ,
  • Mark Cutler,
  • Özlem Türeci,
  • Uǧur Şahin,
  • Kayvon Modjarrad,
  • Kena A. Swanson and
  • Nicholas Kitchin
  • + 7 authors+ 2 authors

We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, phase 2/3, open-label, clinical trial of a single dose (30 μg) of an Omicron XBB.1.5-adapted BNT162b2 monovalent mRNA vaccine. The trial included heal...

  • Review
  • Open Access
8 Citations
4,268 Views
13 Pages

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review

  • Karen Cortés-Sarabia,
  • Mayralina Gutiérrez-Torres,
  • Escarlet Maleny Mendoza-Renteria,
  • Marco Antonio Leyva-Vázquez and ,
  • Amalia Vences-Velázquez,
  • Daniel Hernández-Sotelo,
  • Fredy Omar Beltrán-Anaya,
  • Oscar Del Moral-Hernández and
  • Berenice Illades-Aguiar
  • + 4 authors+ 0 author

The BNT162b2 Pfizer/BioNTech vaccine was the first emergency approved vaccine during the COVID-19 pandemic. The aim of this systematic review was to examine the variations in the humoral immune response induced by the administration of the BNT162b2 v...

(This article belongs to the Special Issue Assessment of Post-COVID-19 Complications and Vaccination Efficacy)
  • Article
  • Open Access
8 Citations
3,634 Views
16 Pages

Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan

  • Atsuhiko Sakamoto,
  • Michinobu Yoshimura,
  • Ryota Itoh,
  • Ryo Ozuru and ,
  • Kazunari Ishii,
  • Yusuke Sechi,
  • Shigeki Nabeshima and
  • Kenji Hiromatsu
  • + 3 authors+ 0 author

Analysis of longitudinal dynamics of humoral immune responses to the BNT162b2 COVID-19 vaccine might provide useful information to predict the effectiveness of BNT162b2 in preventing SARS-CoV-2 infection. Herein, we measure anti-RBD IgG at 1, 3 and 6...

(This article belongs to the Special Issue Effectiveness, Safety and Immunogenicity of SARS-CoV-2 Vaccines)
  • Article
  • Open Access
59 Citations
110,528 Views
13 Pages

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents

  • Suyanee Mansanguan,
  • Prakaykaew Charunwatthana,
  • Watcharapong Piyaphanee,
  • Wilanee Dechkhajorn and ,
  • Akkapon Poolcharoen and
  • Chayasin Mansanguan
  • + 1 author+ 0 author

This study focuses on cardiovascular manifestation, particularly myocarditis and pericarditis events, after BNT162b2 mRNA COVID-19 vaccine injection in Thai adolescents. This prospective cohort study enrolled students aged 13–18 years from two...

(This article belongs to the Special Issue Changes in Tropical and Infectious Disease Epidemiology Following the World Re-opening)
  • Article
  • Open Access
6 Citations
5,101 Views
13 Pages

The BNT162b2 mRNA COVID-19 Vaccine Increases the Contractile Sensitivity to Histamine and Parasympathetic Activation in a Human Ex Vivo Model of Severe Eosinophilic Asthma

  • Luigino Calzetta,
  • Alfredo Chetta,
  • Marina Aiello,
  • Annalisa Frizzelli and ,
  • Josuel Ora,
  • Enrico Melis,
  • Francesco Facciolo,
  • Lorenzo Ippoliti,
  • Andrea Magrini and
  • Paola Rogliani
  • + 5 authors+ 0 author

28 January 2023

The BNT162b2 COVID-19 vaccine is composed of lipid-nanoparticles (LNP) containing the mRNA that encodes for SARS-CoV-2 spike glycoprotein. Bronchospasm has been reported as an early reaction after COVID-19 mRNA vaccines in asthmatic patients. The aim...

(This article belongs to the Special Issue Vaccine Candidate against SARS-CoV-2)
  • Article
  • Open Access
9 Citations
3,802 Views
12 Pages

Antibody Response Induced by BNT162b2 and mRNA-1273 Vaccines against the SARS-CoV-2 in a Cohort of Healthcare Workers

  • Juan F. Delgado,
  • Antoni Berenguer-Llergo,
  • Germà Julià,
  • Gema Navarro and ,
  • Mateu Espasa,
  • Sara Rodríguez,
  • Noemí Sánchez,
  • Eva Van Den Eynde,
  • Marta Navarro and
  • María J. Amengual
  • + 9 authors+ 4 authors

7 June 2022

The aim of this study was to characterize the antibody response induced by SARS-CoV-2 mRNA vaccines in a cohort of healthcare workers. A total of 2247 serum samples were analyzed using the Elecsys® Anti-SARS-CoV-2 S-test (Roche Diagnostics Intern...

(This article belongs to the Topic Infectious Diseases)
  • Article
  • Open Access
11 Citations
3,313 Views
11 Pages

Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19

  • Dong-In Kim,
  • Seo Jin Lee,
  • Soonju Park,
  • Paul Kim and ,
  • Sun Min Lee,
  • Nakyung Lee,
  • David Shum,
  • Dong Ho Kim and
  • Eui Ho Kim
  • + 4 authors+ 0 author

4 November 2022

During the COVID-19 pandemic, vaccines were developed based on various platform technologies and were approved for emergency use. However, the comparative analysis of immunogenicity and durability of vaccine-induced antibody responses depending on va...

(This article belongs to the Special Issue Immune Responses to COVID-19 Vaccines)
  • Article
  • Open Access
6 Citations
2,680 Views
13 Pages

Safety and Humoral and Cellular Immunogenicity of the BNT162b2 SARS-CoV-2 Vaccine in Liver-Transplanted Adolescents Compared to Healthy Adolescents

  • Palittiya Sintusek,
  • Supranee Buranapraditkun,
  • Siriporn Khunsri,
  • Varattaya Saengchaisukhonkit and ,
  • Preeyaporn Vichaiwattana,
  • Donchida Srimuan,
  • Thanunrat Thongmee and
  • Yong Poovorawan
  • + 3 authors+ 0 author

16 August 2022

Since BNT162b2 was approved to prevent COVID-19 in children, we aim to compare the safety and immunogenicity of the BNT162b2 vaccine in liver-transplanted (LT) and healthy adolescents. LT and healthy adolescents received two doses of 30 µg of B...

(This article belongs to the Special Issue Immune Response after Vaccination against SARS-COV-2 in Patients with Chronic Diseases)
  • Article
  • Open Access
1 Citations
1,991 Views
15 Pages

A Study to Investigate the Safety and Immunogenicity of Monovalent Omicron LP.8.1-Adapted BNT162b2 COVID-19 Vaccine in Adults ≥ 65 Years of Age and High-Risk Adults 18–64 Years of Age (Preliminary Results)

  • Rucha Dadhe,
  • Juleen Gayed,
  • Muneeb Iqbal,
  • Rohit Solan and ,
  • Han Wu,
  • Hua Ma,
  • Xia Xu,
  • Federico J. Mensa,
  • Todd Belanger and
  • Kelly Lindert
  • + 13 authors+ 8 authors

15 April 2026

Background/Objectives: This study evaluated the Omicron LP.8.1 variant-adapted BNT162b2 mRNA vaccine (LP.8.1-adapted BNT162b2). Methods: This analysis is part of an ongoing phase 3 open-label study evaluating the immunogenicity, safety, and tolerabil...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)
  • Brief Report
  • Open Access
6 Citations
2,872 Views
6 Pages

Short-Term Drop in Antibody Titer after the Third Dose of SARS-CoV-2 BNT162b2 Vaccine in Adults

  • Jonas Herzberg,
  • Bastian Fischer,
  • Heiko Becher,
  • Ann-Kristin Becker and ,
  • Human Honarpisheh,
  • Salman Yousuf Guraya,
  • Tim Strate and
  • Cornelius Knabbe
  • + 3 authors+ 0 author

Little is known about the longevity of antibodies after a third dose of the mRNA-based SARS-CoV-2 vaccine BNT162b2 (BioNTech/Pfizer, Mainz, Germany). Therefore, serum antibody levels were evaluated after a third dose of BNT162b2 in healthy adult heal...

(This article belongs to the Special Issue Effectiveness, Safety and Immunogenicity of SARS-CoV-2 Vaccines)
  • Article
  • Open Access
10 Citations
3,665 Views
15 Pages

Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents

  • Thanyawee Puthanakit,
  • Napaporn Chantasrisawad,
  • Kirana Yoohat,
  • Rapisa Nantanee and ,
  • Jiratchaya Sophonphan,
  • Thutsanun Meepuksom,
  • Pimpayao Sodsai,
  • Supranee Phanthanawiboon,
  • Watsamon Jantarabenjakul and
  • Pope Kosalaraksa
  • + 6 authors+ 1 author

30 September 2022

Primary series vaccination with BNT162b2 followed by a booster 5 months later has been recommended for healthy adolescents. We aimed to describe the immunogenicity in a fractional dose of BNT162b2. Adolescents aged 12–18 years were randomized i...

(This article belongs to the Topic Global Analysis of SARS-CoV-2 Serology, Part 2)
  • Article
  • Open Access
14 Citations
3,787 Views
15 Pages

Immunogenicity and Reactogenicity of mRNA BNT162b2 COVID-19 Vaccine among Thai Adolescents with Chronic Diseases

  • Napaporn Chantasrisawad,
  • Thanyawee Puthanakit,
  • Auchara Tangsathapornpong,
  • Chonnamet Techasaensiri and ,
  • Wanatpreeya Phongsamart,
  • Detchvijitr Suwanpakdee,
  • Peera Jaruampornpan,
  • Jiratchaya Sophonphan,
  • Piyarat Suntarattiwong and
  • Tawee Chotpitayasunondh
  • + 5 authors+ 0 author

Adolescents with underlying diseases are at risk of severe COVID-19. The immune response of BNT162b2 may be poor among immunocompromised adolescents. We aim to describe immunogenicity of mRNA BNT162b2 among adolescents who are immunocompromised or ha...

(This article belongs to the Topic Global Analysis of SARS-CoV-2 Serology)
  • Article
  • Open Access
7 Citations
3,815 Views
12 Pages

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents

  • Pavinee Assavavongwaikit,
  • Napaporn Chantasrisawad,
  • Orawan Himananto,
  • Chayapa Phasomsap and ,
  • Pintusorn Klawaja,
  • Sapphire Cartledge,
  • Rachaneekorn Nadsasarn,
  • Thidarat Jupimai,
  • Surinda Kawichai and
  • on behalf of the Study Team
  • + 7 authors+ 2 authors

8 July 2022

Despite the BNT162b2 vaccination coverage, rapid transmission of Omicron SARS-CoV-2 has occurred, which is suspected to be due to the immune escape of the variant or waning vaccine efficacy of multiple BNT162b2 vaccination doses. Our study aims to co...

(This article belongs to the Special Issue Immune Responses to COVID-19 Vaccines)
  • Article
  • Open Access
3 Citations
2,676 Views
15 Pages

Effect of SARS-CoV-2 Infection and BNT162b2 Vaccination on the mRNA Expression of Genes Associated with Angiogenesis

  • Paulina Wigner-Jeziorska,
  • Edyta Janik-Karpińska,
  • Marta Niwald,
  • Joanna Saluk and
  • Elżbieta Miller

8 November 2023

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), discovered in December 2019 in Wuhan, China, caused the coronavirus disease 2019 (COVID-19). Due to the rate of spread of this virus, the World Health Organization, in March 2020, recognis...

(This article belongs to the Special Issue Molecular Research on Coronavirus: Pathogenic Mechanism, Antiviral Drugs and New Vaccines)
  • Article
  • Open Access
46 Citations
6,218 Views
9 Pages

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2

  • Stilla Bauernfeind,
  • Bernd Salzberger,
  • Florian Hitzenbichler,
  • Karolina Scigala and ,
  • Sebastian Einhauser,
  • Ralf Wagner,
  • André Gessner,
  • Josef Koestler and
  • David Peterhoff
  • + 4 authors+ 0 author

27 September 2021

It is not clear whether there is an association between adverse reactions and immune response after vaccination. Seven hundred and thirty-five vaccinees from our University Medical Center vaccination clinic provided information about sex, age and adv...

  • Brief Report
  • Open Access
4 Citations
5,441 Views
7 Pages

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

  • Farah M. Shurrab,
  • Duaa W. Al-Sadeq,
  • Haissam Abou-Saleh,
  • Nader Al-Dewik and ,
  • Amira E. Elsharafi,
  • Fatima M. Hamaydeh,
  • Bushra Y. Abo Halawa,
  • Tala M. Jamaleddin,
  • Huda M. Abdul Hameed and
  • Gheyath K. Nasrallah
  • + 9 authors+ 4 authors

25 January 2022

The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the...

(This article belongs to the Special Issue Current Understanding of Immune Response after COVID-19 Vaccination)
  • Article
  • Open Access
54 Citations
8,155 Views
15 Pages

Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals ≥12 Years Old: A Phase 2/3 Trial

  • Juleen Gayed,
  • Oyeniyi Diya,
  • Francine S. Lowry,
  • Xia Xu and ,
  • Vishva Bangad,
  • Federico Mensa,
  • Jing Zou,
  • Xuping Xie,
  • Yanping Hu and
  • Nicholas Kitchin
  • + 16 authors+ 11 authors

24 January 2024

Vaccination remains an important mitigation tool against COVID-19. We report 1-month safety and preliminary immunogenicity data from a substudy of an ongoing, open-label, phase 2/3 study of monovalent Omicron XBB.1.5-adapted BNT162b2 (single 30-μg...

  • Article
  • Open Access
2 Citations
2,686 Views
13 Pages

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments

  • Abed Agbarya,
  • Ina Sarel,
  • Tomer Ziv-Baran,
  • Orna Schwartz and ,
  • Yelena Shechtman,
  • Ella Kozlener,
  • Rasha Khoury,
  • Mohammad Sheikh-Ahmad,
  • Leonard Saiegh and
  • Ronen Brenner
  • + 8 authors+ 3 authors

26 September 2023

The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the...

  • Article
  • Open Access
56 Citations
5,069 Views
13 Pages

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers

  • Louise Benning,
  • Maximilian Töllner,
  • Asa Hidmark,
  • Matthias Schaier and ,
  • Christian Nusshag,
  • Florian Kälble,
  • Paula Reichel,
  • Mirabel Buylaert,
  • Julia Grenz and
  • Claudius Speer
  • + 11 authors+ 6 authors

4 August 2021

Despite limited data on safety and immunogenicity, heterologous prime-boost vaccination is currently recommended for individuals with ChAdOx1 nCoV-19 prime immunization in certain age groups. In this prospective, single-center study we included 166 h...

(This article belongs to the Special Issue Vaccination Strategies for COVID-19)
  • Article
  • Open Access
3,751 Views
15 Pages

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

  • Passakorn Wanchaijiraboon,
  • Panot Sainamthip,
  • Nattaya Teeyapun,
  • Sutima Luangdilok and ,
  • Yong Poovorawan,
  • Nasamon Wanlapakorn,
  • Suebpong Tanasanvimon,
  • Virote Sriuranpong,
  • Thiti Susiriwatananont and
  • Nussara Pakvisal
  • + 6 authors+ 1 author

3 February 2023

Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who...

(This article belongs to the Special Issue Adverse Events of COVID-19 Vaccines)
  • Article
  • Open Access
11 Citations
4,641 Views
13 Pages

Effect of Heterologous Vaccination Strategy on Humoral Response against COVID-19 with CoronaVac plus BNT162b2: A Prospective Cohort Study

  • Hakan Demirhindi,
  • Burak Mete,
  • Ferdi Tanir,
  • Ertan Kara and ,
  • Filiz Kibar,
  • Salih Cetiner,
  • Aslihan Candevir and
  • Sukriye Ece Akti
  • + 3 authors+ 0 author

28 April 2022

This study aimed to evaluate the mixed and homogeneous application of the inactivated SARS-CoV-2 vaccine CoronaVac (CV) and the mRNA vaccine BNT162b2 (BNT). This prospective cohort study included 235 health care workers who had received two prime sho...

(This article belongs to the Special Issue Vaccination Strategies for SARS-CoV-2, the Causative Agent of COVID-19)
  • Article
  • Open Access
8 Citations
3,355 Views
8 Pages

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster

  • Chin Shern Lau,
  • John Thundyil,
  • May Lin Helen Oh,
  • Soon Kieng Phua and ,
  • Ya Li Liang,
  • Yanfeng Li,
  • Jianxin Huo,
  • Yuhan Huang,
  • Biyan Zhang and
  • Tar Choon Aw
  • + 6 authors+ 1 author

8 November 2022

Introduction: We documented the total spike antibody (S-Ab), IgG S-Ab and neutralizing antibody (N-Ab) responses of BNT162b2/CoronaVac vaccinees up to 90 days post-booster dose. Methods: We included 32 homologous regimen CoronaVac vaccinees and 136 B...

(This article belongs to the Special Issue The Role of Antibodies in SARS-CoV-2 Infection)
  • Article
  • Open Access
8 Citations
10,442 Views
13 Pages

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222

  • Rapisa Nantanee,
  • Watsamon Jantarabenjakul,
  • Peera Jaru-Ampornpan,
  • Pimpayao Sodsai and ,
  • Orawan Himananto,
  • Jitthiwa Athipunjapong,
  • Jiratchaya Sophonphan,
  • Sira Nanthapisal,
  • Nattiya Hirankarn and
  • Thanyawee Puthanakit
  • + 5 authors+ 0 author

In the era of globally predominant omicron strains, a COVID-19 booster vaccine is needed. Our study aimed to evaluate the immunogenicity of a half-dose BNT162b2 booster after AZD1222 in healthy adults. A randomized trial of volunteers aged 18–6...

(This article belongs to the Section COVID-19 Vaccines and Vaccination)

of 20